CHICAGO — An experimental drug shows the ability to more than double a person’s good cholesterol score, potentially filling a huge gap in cardiovascular care, scientists report. If the findings hold up in a larger trial, the drug, called anacetrapib, stands poised to become the best medication yet for boosting levels of the heart-disease preventer HDL.
Log in
Subscribers, enter your e-mail address for full access to the Science News archives and digital editions.